Corrigendum to "Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency" [Thromb. Res. volume 259 (2026) https://doi.org/10.1016/j.thromres.2026.109616] [0.03%]
“人血浆新型纤维蛋白原浓缩剂在先天性纤维蛋白原缺乏症患者中预防和治疗出血事件的有效性和安全性”一文的勘误(259卷2026页https://doi.org/10.1016/j.thromres.2026.109616)[ thromb. res.]
Claudia Djambas Khayat,Amal El-Beshlawy,Naglaa Omar et al.
Claudia Djambas Khayat et al.
Published Erratum
Thrombosis research. 2026 Mar 4:109633. DOI:10.1016/j.thromres.2026.109633 2026
Physical basis of platelet glycoprotein Ibα binding with von Willebrand factor and with coagulant factor XI on their biological functions [0.03%]
血小板GPIbα与血管性假血友病因子及凝血因子XI相互作用的分子机制及其生理病理功能中的物理基础研究
Masamitsu Nakayama,Satoko Takemoto,Shinichi Goto et al.
Masamitsu Nakayama et al.
von Willebrand factor in hemodialysis patients. Does acquired von Willebrand syndrome occur? [0.03%]
终末期肾病血液透析患者的vWF分析：获得性血管性假血友病是否会发生？
Michele Marchini
Michele Marchini
Introduction and aims: von Willebrand factor (vWF) is a multimeric plasma glycoprotein synthesized by endothelial cells and megakaryocytes that has an essential role in the primary hemostasis, in fact, the high-molecular-...
Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial [0.03%]
体重对低风险肺血栓形成癌患者的临床预后影响——来自ONCO PE试验的启示
Toru Sato,Yoshito Ogihara,Yugo Yamashita et al.
Toru Sato et al.
Implementation of institutional thrombophilia guidelines and electronic medical record tools to reduce inpatient thrombophilia testing and costs [0.03%]
通过实施机构血栓形成指南和电子病历工具减少住院患者血栓形成检查和费用
Muhammad Mubbashir Sheikh,Hatim Attar,Diane Book et al.
Muhammad Mubbashir Sheikh et al.
Obesity and type 2 diabetes mellitus add up to induce platelet hyperreactivity and platelet activation [0.03%]
肥胖和2型糖尿病通过累加作用诱导血小板高反应性和活化
Giuseppe Guglielmini,Emanuela Falcinelli,Michelantonio De Fano et al.
Giuseppe Guglielmini et al.
Background: Platelet hyperreactivity and in vivo platelet activation, effectors of increased cardiovascular risk, have been associated with both type 2 diabetes (T2DM) and obesity, however, whether T2DM and obesity when c...
Rebuttal to correspondence on "Diagnostic accuracy meta-analysis of portal vein thrombosis imaging" [0.03%]
关于“门静脉血栓影像诊断准确性荟萃分析”的来信回复
Laura Girardi,Aurélien Delluc
Laura Girardi
Barriers and facilitators to healthy lifestyle behaviours for people living with post pulmonary embolism syndrome. A qualitative study exploring participants lived experiences [0.03%]
影响肺栓塞后综合症患者健康生活方式的障碍与促进因素定性研究：探索参与者的生活经历
Caoimhe Kenny,Fiona Curran,Olive Lennon et al.
Caoimhe Kenny et al.
Background: People living with post-pulmonary embolism syndrome (PPES) commonly experience persistent dyspnoea, fatigue, reduced exercise tolerance, anxiety, and fear of recurrence. When symptoms continue beyond three mon...
Identifying the spectrum of clinical trajectories in intermediate-high risk pulmonary embolism: A clinical and research imperative [0.03%]
识别中间至高风险肺栓塞临床转归谱系：临床与研究的必要性
Marco Zuin,Roman Chopard,Cecilia Becattini et al.
Marco Zuin et al.
Intermediate-high-risk pulmonary embolism (PE) is characterized by broad clinical, physiologic, and hemodynamic parameters, but its prognostic trajectory is poorly described by current risk stratification tools. New clinical scoring systems...
aPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance [0.03%]
抗磷脂综合征中抗磷脂抗体阳性转换：从定义到临床意义
Angela Di Giorgio,Claudia Carnuccio,Antonio Nesci et al.
Angela Di Giorgio et al.
Antiphospholipid syndrome (APS) is an acquired coagulation disorder with an unclear pathogenesis, diagnosed in the presence of thrombotic events, obstetric complications, or non-thrombotic manifestations, alongside persistently detectable a...